Literature DB >> 11160020

Capsular reactions of Cryptococcus neoformans with polyspecific and oligospecific polyclonal anticapsular antibodies.

T C MacGill1, R S MacGill, T R Kozel.   

Abstract

Monoclonal antibodies to the capsular polysaccharide of Cryptococcus neoformans produce distinct capsular reactions and have biological activities that are determined by serotype specificity. In the present study, polyclonal rabbit anticapsular antibodies were cross-absorbed to produce serotype specificities similar to those of monoclonal antibodies. The results showed that polyclonal and monoclonal antibodies with similar serotype specificities have similar capsular reactions and biological activities.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11160020      PMCID： PMC98004          DOI： 10.1128/IAI.69.2.1189-1191.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  10 in total

1.  Characterization of anticapsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsule.

Authors:  T R Kozel; B C deJong; M M Grinsell; R S MacGill; K K Wall
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

2.  Biological correlates of capsular (quellung) reactions of Cryptococcus neoformans.

Authors:  T C MacGill; R S MacGill; A Casadevall; T R Kozel
Journal:  J Immunol       Date:  2000-05-01       Impact factor: 5.422

3.  C3 shunt activation in human serum chelated with EGTA.

Authors:  D P Fine; S R Marney; D G Colley; J S Sergent; R M Des Prez
Journal:  J Immunol       Date:  1972-10       Impact factor: 5.422

4.  Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity.

Authors:  S J Devi; R Schneerson; W Egan; T J Ulrich; D Bryla; J B Robbins; J E Bennett
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

5.  Acute lethal toxicity following passive immunization for treatment of murine cryptococcosis.

Authors:  A C Savoy; D M Lupan; P B Manalo; J S Roberts; A M Schlageter; L C Weinhold; T R Kozel
Journal:  Infect Immun       Date:  1997-05       Impact factor: 3.441

Review 6.  Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model.

Authors:  S J Devi
Journal:  Vaccine       Date:  1996-06       Impact factor: 3.641

7.  The capsule of cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages.

Authors:  T R Kozel; E C Gotschlich
Journal:  J Immunol       Date:  1982-10       Impact factor: 5.422

8.  Antigenic characterization of Cryptococcus neoformans serotypes and its application to serotyping of clinical isolates.

Authors:  R Ikeda; T Shinoda; Y Fukazawa; L Kaufman
Journal:  J Clin Microbiol       Date:  1982-07       Impact factor: 5.948

9.  Benzoquinone activation of Cryptococcus neoformans capsular polysaccharide for construction of an immunoaffinity column.

Authors:  T R Kozel; C A Hermerath
Journal:  J Immunol Methods       Date:  1988-02-24       Impact factor: 2.303

10.  Occurrences, immunoglobulin classes, and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neoformans glucuronoxylomannan.

Authors:  D C Houpt; G S Pfrommer; B J Young; T A Larson; T R Kozel
Journal:  Infect Immun       Date:  1994-07       Impact factor: 3.441
  10 in total
  3 in total

1.  Protective and immunochemical activities of monoclonal antibodies reactive with the Bacillus anthracis polypeptide capsule.

Authors:  Thomas R Kozel; Peter Thorkildson; Suzanne Brandt; William H Welch; Julie A Lovchik; David P AuCoin; Julpohng Vilai; C Rick Lyons
Journal:  Infect Immun       Date:  2006-10-23       Impact factor: 3.441

2.  Monoclonal antibodies reactive with immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans.

Authors:  Suzanne Brandt; Peter Thorkildson; Thomas R Kozel
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

3.  Antibodies produced in response to Cryptococcus neoformans pulmonary infection in mice have characteristics of nonprotective antibodies.

Authors:  Oscar Zaragoza; Arturo Casadevall
Journal:  Infect Immun       Date:  2004-07       Impact factor: 3.441
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.